Proton beam therapy targets cancer accurately, minimising side effects but faces challenges in cost and accessibility.
Human Body Imaging
Cancer is a product of cellular changes that cause disease through the uncontrolled growth and division of cells. Over the past 150 years, many hypotheses have been proposed to explain the origin of cancer cells. These include the unregulated proliferation of cancer cells, metastasis and the histological classification of the cancer tissue (benign or malignant tumour).
In 1845, Rudolf Virchow found abnormal increases in white blood cells in some patients and, in 1847, identified the condition as a blood disease called leukämie (leukaemia). In 1857, Virchow was the first to identify chordoma, a tumour developed at the skull’s base. Also, in 1858, he presented that cancer cells are the body’s own cells.
Currently, the most accepted theory of cancer is based on the hysteron proteron of the somatic mutation theory (SMT). In this model, the first event (mutations) occurs after the cell has been transformed from a normal cell to a cancer cell via a process termed carcinogenesis. These mutations have increasingly been perceived as the causal event in the origin of the vast majority of cancers.
Currently, this model is challenged by a growing amount of experimental data and arguments that could either not be explained by the model or contradict this model.
One study of three subtypes of ependymoma (glioma) brain tumours found that one subtype carried an intrachromosomal translocation (a segment breaking off the chromosome and rejoining it at a different location): this creates a new tumour-driving gene. The second subtype lacked tumour-driving mutations and had epigenetic modifications compared to the third subtype, which had neither gene mutations nor epigenetic aberrations.
Furthermore, the fact that normal tissues can display massive genetic changes, including changes in cancer-initiating and cancer-driving genes. Over the past few decades, several transfer experiments have demonstrated tumour-suppressing effects on normal cytoplasm. These include mitochondrial transfer, which has the ability to suppress tumour growth. This could be demonstrated – despite the presence of cancerous nuclear genomes – by showing the introduction of non-cancerous mitochondria into highly malignant breast cancer cells. This approach reversed the malignancy and down-regulated several oncogenic pathways, such as invasion and in vivo tumour growth.
Moreover, several non-genotoxic (non-mutagenic) carcinogens, including dichlorobenzene and chloroform, initiate cancer formation. Other oncological theories include oxidative phosphorylation, which results in cellular energy loss and highly impacts cancer formation.
Currently, several imaging modalities are available to clinicians who diagnose, stage and treat human cancer: X-ray (plain film and computed tomography), ultrasound, magnetic resonance imaging, single-photon emission computed tomography, positron emission tomography and optical imaging. Of these, only four (MRI, CT, PET and SPECT) are capable of 3-D detection of cancer anywhere in the human body.
You Are Here: Home » cancerProton beam therapy targets cancer accurately, minimising side effects but faces challenges in cost and accessibility.
213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
211At-Parthanatine, targeting PARP1 with alpha radiation, promises precise cancer therapy, especially for high-risk neuroblastomas.
Astatine-211 Sodium Astatide, evolving thyroid treatment, enters trials, promising enhanced precision and safety over traditional Iodine-131 NaI therapy.
211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
Theragnomics melds theranostics and radiomics, promising targeted cancer therapies with improved outcomes through precision diagnostics and treatment adaptation.
Therapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
Advancing cancer care, proton therapy offers precise treatment with fewer side effects, revolutionising patient experiences.
Radiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
CAR T-cell therapy revolutionises cancer care, bringing hope where traditional treatments have been insufficient.
Thorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.
Neuroblastoma Targeting Agents offer innovative diagnostic and therapeutic options, revolutionizing treatment with precise targeting and efficacy.
Technetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
Gallium-68 and Lutetium-177 labelled Girentuximab mark a breakthrough in diagnosing and treating hepatocellular carcinoma.
Utilising CXCR4 targeting agents with labelled ligands marks a breakthrough in treating haematological malignancies effectively.
Folate Receptor Targeting Agents revolutionise cancer diagnosis and treatment with Fluorine-18 and Rhenium-188 labelling.
FAPI revolutionises oncology with precise Gallium-68 diagnostics and targeted Lutetium-177 therapy for cancer.
PSMA targeting agents revolutionise prostate cancer care with precise diagnostics and targeted therapeutic approaches.
211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
225Ac-FPI-2059 targets NTSR1 in cancer cells, offering a novel approach in pancreatic cancer treatment.
Theranostics merges diagnostics and therapy, revolutionising personalised medicine with genetic profiling and targeted treatment strategies.
Medical imaging crucially enhances oncology, aiding early cancer detection and effective treatment planning.
Lasers in medicine offer revolutionary precision and versatility, significantly advancing healthcare through diverse, minimally invasive applications.
Immuno-PET merges monoclonal antibodies with PET imaging, transforming precision oncology through enhanced tumor detection and monitoring.
CEST MRI reveals molecular tissue details, enhancing early disease diagnosis without external contrast agents.
Micro-ultrasound's detailed imaging necessitates expert analysis, mindful safety practices, and promises future multimodal diagnostic integrations.
Lymphoseek offers targeted, efficient sentinel lymph node mapping, improving cancer staging and reducing surgical morbidity.
Technetium-99m sodium pertechnetate is pivotal for brain, thyroid, cardiac imaging, and cancer detection in nuclear medicine.
Lung cancer's high mortality demands early detection; advances like low-dose CT and photon-counting CT improve noninvasive, accurate screening outcomes.
Iodine-123 iobenguane is vital for detecting, staging, and monitoring neuroendocrine tumours, guiding treatment, and offering prognostic insights.
Machine learning revolutionises cancer diagnostics, enabling early detection and personalised treatment for improved prognosis.
PET probes to investigate the movement of nucleosides across biological membranes.
Application of aptamers in drug delivery systems and radiopharmacy.